Sarepta Therapeutics Inc Stock Nasdaq
Equities
US0023461041
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 1.89B | Sales 2025 * | 2.76B | Capitalization | 12.63B |
---|---|---|---|---|---|
Net income 2024 * | 264M | Net income 2025 * | 883M | EV / Sales 2024 * | 6.14 x |
Net cash position 2024 * | 1.03B | Net cash position 2025 * | 2.54B | EV / Sales 2025 * | 3.66 x |
P/E ratio 2024 * |
41.6
x | P/E ratio 2025 * |
13.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.13% |
Latest transcript on Sarepta Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+313.59% | 8.49B |